These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36732734)

  • 21. Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry.
    Behr J; Bonella F; Günther A; Koschel D; Prasse A; Pittrow D; Klotsche J; Kreuter M;
    BMC Pulm Med; 2023 Feb; 23(1):64. PubMed ID: 36774483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trial.
    Dowman LM; May AK; Hill CJ; Bondarenko J; Spencer L; Morris NR; Alison JA; Walsh J; Goh NSL; Corte T; Glaspole I; Chambers DC; McDonald CF; Holland AE
    BMC Pulm Med; 2021 Nov; 21(1):361. PubMed ID: 34758808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
    Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
    Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.
    Prior TS; Hilberg O; Shaker SB; Davidsen JR; Hoyer N; Birring SS; Bendstrup E
    BMC Pulm Med; 2019 Dec; 19(1):255. PubMed ID: 31856786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
    Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
    BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial.
    Bates A; Rushbrook S; Shapiro E; Grocott M; Cusack R
    Trials; 2020 Nov; 21(1):929. PubMed ID: 33203440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic respiratory and functional rehabilitation protocol for intensive care unit patients affected by COVID-19: a structured summary of a study protocol for a randomised controlled trial.
    Carvalho AC; Moreira J; Cubelo P; Cantista P; Branco CA; Guimarães B
    Trials; 2021 Apr; 22(1):268. PubMed ID: 33845878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease.
    Maher TM; Schiffman C; Kreuter M; Moor CC; Nathan SD; Axmann J; Belloni P; Bengus M; Gilberg F; Kirchgaessler KU; Wijsenbeek MS
    Respir Res; 2022 Nov; 23(1):307. PubMed ID: 36369156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
    Wijsenbeek MS; Bendstrup E; Valenzuela C; Henry MT; Moor CC; Jouneau S; Fois AG; Moran-Mendoza O; Anees S; Mirt M; Bengus M; Gilberg F; Kirchgaessler KU; Vancheri C
    Adv Ther; 2021 Jul; 38(7):4040-4056. PubMed ID: 34117601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life.
    Scallan C; Strand L; Hayes J; Kadura S; Collins B; Ho L; Spada C; Canestaro W; Kolb M; Raghu G
    Eur Respir J; 2022 Jan; 59(1):. PubMed ID: 34112729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
    Wilson AM; Clark AB; Cahn T; Chilvers ER; Fraser W; Hammond M; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett DR; Whyte M;
    JAMA; 2020 Dec; 324(22):2282-2291. PubMed ID: 33289822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry.
    Ryerson CJ; Tan B; Fell CD; Manganas H; Shapera S; Mittoo S; Sadatsafavi M; To T; Gershon A; Fisher JH; Johannson KA; Hambly N; Khalil N; Marras TK; Morisset J; Wilcox PG; Halayko AJ; Khan MA; Kolb M
    Can Respir J; 2016; 2016():3562923. PubMed ID: 27445528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.
    Noth I; Cottin V; Chaudhuri N; Corte TJ; Johannson KA; Wijsenbeek M; Jouneau S; Michael A; Quaresma M; Rohr KB; Russell AM; Stowasser S; Maher TM;
    Eur Respir J; 2021 Jul; 58(1):. PubMed ID: 33419890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study.
    Wijsenbeek M; Bendstrup E; Valenzuela C; Henry MT; Moor C; Bengus M; Perjesi A; Gilberg F; Kirchgaessler KU; Vancheri C
    Adv Ther; 2019 Jan; 36(1):232-243. PubMed ID: 30506309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
    Nasser M; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Hachulla E; Jouneau S; Le Lay K; Cottin V
    Respir Res; 2021 May; 22(1):162. PubMed ID: 34030695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.